Journal of Positive Psychology & Wellbeing
2022, Vol. 6, No. 4, 152 – 158
http://journalppw.com
ISSN 2587-0130

Establishing Pharmacokinetic and Pharmacodynamic Models for Antibiotics Used in Special Paediatric Populations

Abeer Aqeel Mutwalli[1], Essam Mubarak Aljameeli[2], Rayan Mohammed Alharbi[2], Ozoof Abdullah Rashed[2], Asma Hassan Bamumin[2], Huda Ahmed Saed[3], Theaar Saad Alotaibi[4], Anas Omar Bushah[5], Naif Hashim Alrashdi[6], Douha Faisal Alnemari[7]

[1]*Pharm D, King Faisal Hospital, Makkah*
[2]*Pharmacist, King Faisal Hospital, Makkah*
[3]*Pharmacy Technician, King Faisal Hospital, Makkah*
[4]*Pharm D, Mental Health Hospital, Taif*
[5]*Senior Pharmacist, Maternity and Children Hospital, Makkah*
[6]*Pharmacist, Al Aziziyah Children Hospital, Jeddah*
[7]*Pharmacist, Heraa General Hospital, Makaah*

Abstract

It is crucial to determine the proper dosage for the drugs prescribed for neonates. Extrapolating dosages from adults and older children is not a good idea to neonates because of the significant physiological differences that impact the distribution, metabolism, excretion, and absorption of medications. It is now feasible to gather more exact data on the pharmacokinetic characteristics of the research population as well as on an individual, as well as on intra- and interindividual variability, thanks to the widespread application of population pharmacokinetic analysis techniques in neonates. A feature of neonatal pharmacology is the heterogeneity of clinical reactions to single doses of a medication; this phenomenon is associated with interindividual variability in pharmacokinetic and pharmacodynamic outcomes, leading to a limited degree of predictability. In order to determine optimal dosages for antibiotics used in specific paediatric populations, this research will examine the fundamentals of pharmacokinetic (PK) and pharmacodynamic (PD) models.

Keywords*: pharmacokinetics, pharmacodynamics, antibiotic, paediatric.*

Introduction

Determining the appropriate dosage for medications utilized in the care of the infant is crucial. It is not suitable to calculate doses for neonates using information from adults and older kids due to their primary physiological differences that impact drug distribution, metabolism, excretion, and absorption. Since sepsis is a major factor in neonatal morbidity and mortality, antibiotics are the most often prescribed medication in clinical practice for newborns, especially those referred to neonatal intensive care units (NICUs) [1].

2874 newborns out of every 100,000 live births are projected to acquire sepsis, with a 17.6% mortality risk, according to a recent systematic review and meta-analysis on global incidence and mortality. Sepsis in neonates is not always associated with the same type of sepsis (early- or late-onset), depending on factors such as birth weight and gestational age. The incidence of The study examined the differences in rates of late-onset sepsis (LOS) and early-onset sepsis (EOS) between preterm babies (88.5/1000 vs. 13.5/1000) and full-term newborns. (15.05/1000 live births vs. 0.5/1000

live births) is higher in premature patients. Approximately 75 percent of term babies weigh less than 1500 g at delivery, and more than 80 percent of those who weigh less than 1000 g are treated with antibiotics [2].

When treating patients with suspected meningitis, third-generation cephalosporins along with ampicillin and aminoglycosides are the recommended course of empiric antibiotic therapy for EOS. Different antibiotic combinations may be used in relation to LOS depending on the Antibiotic resistance risk variables, case severity, illness source, and local microbial resistance profiles. However, there is no general guideline for empiric therapy in this regard [3].

Although there is specific dosage information available, the use of antibiotics in newborns is nevertheless prevalent in many circumstances. In addition, the intricacy of prescription arises from the necessity of promptly adjusting the dosage of antibiotics to the extent of metabolic immaturity of the newborn organs (liver, kidney, distribution volumes); the development as well as the physiological processes' functional maturity can impact the pharmacokinetic processes, resulting in elevated toxicity or decreased efficacy [3].

More accurate data on the pharmacokinetic parameters of the research population as well as of an individual, as well as on differences between and within individuals, have been obtained thanks to the widespread use of population pharmacokinetic analysis methodologies in neonates. Variable clinical reactions to particular medication dosages are a hallmark of neonatal pharmacology. This phenomenon is linked to interindividual variability in pharmacokinetic and pharmacodynamic aspects, leading to a limited degree of predictability. Comprehending drug pharmacokinetics and pharmacodynamics in their whole, along with the clinical features of treatment-receiving patients, is essential to selecting a safe medication and an appropriate dosage [4].

In addition to understanding the fundamental pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the drug, choosing the right dose for a neonate also necessitates understanding the significant effects that organ development may have on the amount of distribution and clearance, both of which could impact a drug's PK/PD. Alternative antibiotic dosing approaches that are more in line with the PK and PD characteristics of the drug are gaining popularity [4].

Aim of study

The purpose of this study is to identify acceptable dosages and to examine the pharmacokinetic (PK) as well as pharmacodynamic (PD) models for antibiotics prescribed to particular kids.

Literature review

Developmental Pharmacokinetics, Applied to Antibiotics

The field of developmental pharmacology delineates how drug effects (pharmacodynamics [PD]) and drug disposition (PK) change as a child grows older (0–18 y). Regulations supporting the development of pediatric medications within a generic framework exist; these regulations also apply to antibiotic development. The three pillars of this framework are as follows: (i) adults and children progress diseases similarly; (ii) both respond similarly to interventions; and (iii) there are appropriate and reliable PD markers (biomarkers, outcome variables) available [5].

Utilizing this structure for antibiotics, regulatory agencies presently believe it is appropriate to infer antimicrobial PD similarity (concentration-response) among patient populations since the medication targets the infectious organism rather than the host (adult or child). To maximize drug research programs and the use of antibiotics in newborns and children, variations in PK and safety are thus the main focus [5].



Figure 1. An example of how pharmacokinetic changes in children and neonates are associated to critical illness and development [8].

Age-Specific Pharmacokinetic Variability

Variability in PK is mostly caused by physiological maturation, organ function, and size. Assuming the absence of medical diseases like cystic fibrosis that may be linked to altered organ function, age has a major role in determining maturation and organ function in the paediatric population. Though some age-related alterations persist throughout childhood, the newborn and infant stages are primarily when physiologic maturation that influences a drug's PK occurs. In general, age has a fairly strong correlation with the development of drug clearance and plays a major role in determining the optimal dosage of drugs in newborns, babies, and early children. However, as children get older, this correlation weakens. The most notable developmental changes take place in the first year of life, starting with a sharp rise in renal function in the first two weeks of birth as a result of increased renal blood flow [6].

Absorption: Numerous age-related variables, such as intraluminal pH, gut motility, and splanchnic blood flow, are important in affecting the degree and pace of medication breakdown and absorption. Because they produce less acid than adults, newborns have an intragastric pH that is comparatively higher (>4 versus 2, respectively). Acid suppressants may be prescribed to newborns and infants with gastroesophageal reflux disease, which may further raise their intragastric pH. Consequently, it was shown that newborns have a higher bioavailability of acid-labile medications including ampicillin, nafcillin, and penicillin G because they are protected in an environment with a higher pH [7].

Distribution: When given on a mg/kg basis, water-soluble antibiotics (such as aminoglycosides, vancomycin, and beta-lactams) have reduced (peak) concentrations and greater volumes of dispersion (Vd) during infancy due to the increased body water levels overall and in extracellular matrix [8].

Elimination: Most antibiotics are primarily eliminated by the kidneys, which is determined by the kidney's renal tubular functions (secretion, reabsorption) and glomerular filtration rate (GFR). For this reason, pharmacometric approaches that personalize the use of antibiotics that are primarily eliminated by the kidneys in a pediatric and neonatal intensive care unit (ICU) should be centered around renal models and renal (patho)physiology. Even with an allometric coefficient (kg0.75), A sigmoid hyperbolic model of human renal development has been described, whereby half of the adult value is obtained should reach 90% of this value by the end of infancy at 48 weeks postmenstrual age. The sharp rise in clearance (CL) in infancy is much more noticeable when it is based on body weight [9].

Pharmacokinetic Changes Associated with Critical Illness in Children and Infants

Numerous antibiotics have been shown to cause pathophysiological changes and consequent PK abnormalities in critically unwell children. However, there are still few and far between juvenile PK data versus the abundance of PK studies that reveal antibiotic PK in critically ill adults. A common result of Fluid replacement and capillary leaks brought on by inflammation, which is exacerbated by hypoalbuminemia, is increased Vd. Changes in antibiotic CL have also been linked to both extremes of renal function (i.e., acute kidney injury requiring renal replacement therapy [RRT] and ARC) and have been documented frequently in pediatric antibiotic research [10].

Metabolism

The medication flows through the organs that metabolize drugs in addition to dispersing throughout the body. Medicines are mostly broken down into metabolites in the liver, which are therefore generally eliminated more easily. Substance metabolism can also occur in the skin, kidneys, and mucosa of the gastrointestinal tract. Peptide The isozymes P-450 (CYP) and UDP-glucuronosyltransferase (UGT) are examples Comprising phase I and phase II enzymes involved in drug metabolism that can process drugs [7].

Over the course of childhood, the majority of metabolizing enzymes grow and reach their full potential. Although CYP3A4 metabolizes almost half of all pharmaceuticals available, newborns' CYP3A4 activity is less than 10% of that of adults. Compared to adults, newborns have less developed forms of some additional CYP isozymes that metabolize drugs, such as CYP2E1, CYP2D6, CYP2C9, and CYP2C19. It is possible to detect these enzymes shortly after birth. The most common enzyme in

neonates, CYP3A7 is expressed in the fetal liver [7].

Pharmacodynamics

By optimizing The PD characteristic of an antimicrobial agent can help optimize therapy when used to inhibit or eliminate infections or possibly suppress the development of resistance towards the goal of curing or successfully treating infectious diseases. Adults and paediatrics have different exposure-response relationships in terms of predictability [11].

Standard antibiotic dosages often give a baseline exposure to elicit a predictable clinical response in adults, while underlying genetic and clinical variables may modify response. In contrast, there is a significant range in the exposure to antibiotics across the paediatric age range, primarily due to the child's stage of immunologic and physiological maturity. Because of these physiological and immunological variations, a child's exposure to a drug is less predictable than an adult's. It is reasonable to presume that paediatric antimicrobial effects (microbiologic and clinical cure) will be comparable to those in adults after exposure is modified in children to attain adult equivalency [11].

The minimum inhibitory concentration (MIC)

Numerous in vitro assays can be used to evaluate the classic binary phenotypic measure of antibiotic action (growth/no growth). Biological variation (differences between strains within a species) and assay variation (differences between and within laboratories in the preparation of inoculums, media, incubation temperatures, incubation times, and antibiotic stock solutions) are the sources of the intrinsic variability in MIC measurements. The predominate pre-existing bacterial population is typically reflected in the measured minimum inhibitory concentration (MIC), which may be susceptible. However, suppression of small resistant subpopulations within the greater susceptible bacterial population may be necessary for a successful microbiological treatment. Utilizing The exposure-response relationship in static or dynamic in vitro or in vivo infection models can be quantitatively assessed to identify the exposure metric most strongly correlated with PD activity [12].

Monte Carlo Simulation

A PD exposure target or index should be clearly established and included (together with age-specific PK data) into Monte Carlo simulations in order to determine the optimal dosage a treatment plan that produces both clinical and microbiologic cures (and even resistance suppression). Pathogen susceptibility and antibiotic exposure, as represented by free drug peak concentration over MIC (Cmax/MIC, associated with aminoglycosides), AUC24/MIC associated with fluoroquinolones, or the duration beta-lactam-associated free drug concentrations that stay above the minimum inhibitory concentration (fT>MIC), must be integrated into The different PD indices for each antibiotic class [13].

As of right now, preclinical in vitro models have been the main source of the objectives of PD exposure to antibiotics, with very little validation in clinical trials. Additionally, the adult patients in these few human clinical studies were the subjects of retrospective research. Therefore, there is a clear need for well-designed trials in paediatric participants to validate the Parkinson's disease (PD) targets of antimicrobial medicines that were obtained from preclinical and adult data, ideally undertaken prospectively [13].

The technique of measuring a medication's concentration at predetermined intervals, known as therapeutic drug monitoring (TDM), has been used to improve individual dosage regimens in order to keep the medication concentration steady within the intended therapeutic window or range that is established by the PK/PD indices of each drug. It has historically been mainly employed to monitor medications with restricted therapeutic ranges, high PK variability, or notable side effects outside of the prescribed range [14].

The antibiotic resistance crisis

Overall life expectancy has grown due to the large decrease in child mortality caused by the availability of antibiotic medication. But more and more bacteria are developing resistance to the many antibiotics that are currently being used, leading to the emergence of multidrug-resistant (MDR) microorganisms. The increased morbidity and mortality caused by antibiotic resistance often stems from inadequate antibiotic treatment being delayed.

The innate capacity of microorganisms to proliferate in the presence of elevated antibiotic concentrations is known as antibiotic resistance (AMR). When resistant bacteria are able to proliferate and to develop at antibiotic concentrations that are fatal to further strains of the same species, it is frequently assessed by figuring out the antibiotic's minimum inhibitory concentration (MIC) [15].

The flavors of there are differences in antibiotic resistance. The presence or lack of particular structures can result in natural intrinsic resistance, which is one factor that makes antibiotics ineffective. Nevertheless, chromosomal gene alterations or horizontal gene transfer from plasmids or chromosomes can also cause bacteria to become resistant to antibiotics. Resistance can be caused by several mechanisms. Three primary mechanistic classes of resistance are used to classify these molecular mechanisms: lowering of antibiotic concentrations within cells, alteration of the antibiotic target, and antibiotic inactivation [15].

Clinical trials in paediatrics

Because there are fewer paediatric patients available for clinical trials than there are adult patients, parents may be reluctant to enroll their children in clinical trials, among other methodological and logistical challenges. These factors all contribute to the additional complexity of drug development when infants, children, and adolescents are included in clinical trials. In addition, as children are seen as a vulnerable group, there are ethical guidelines meant to provide extra protection for them when they participate in clinical research [16].

Because allocating a patient to a placebo arm in a paediatric trial can raise ethical concerns, choosing a control group can be more difficult than in an adult trial. Children, in contrast to adults, are unable to provide their consent to participate in clinical trials, and the amount of danger that they can be exposed to during an inquiry must be limited according to whether the intervention under study has the potential to directly benefit the kid. As a result, studies involving children must only be ethically and scientifically justified, and if feasible, data supporting the safe and efficient use of pharmaceutical goods in children should come from other sources (such as adult populations) [16].

Creating child dosage schedules based on evidence

Paediatric medication dosages taken from adult data cannot guarantee optimal therapeutic efficacy and safety due to predicted changes in drug dependant PK and PD among children of different ages and the existing lack of understanding on organ specific ontogeny processes. Rather, it would be better to create pediatric PKPD models that would suggest dosage schedules for the whole pediatric population. A multi-step method (Figure 2) has been suggested to arrive at evidenc-based dosage regimens for children. This multi-phase method depends on the population approach and is founded on the learning-confirming premise [17].



Figure 2. a multi-step strategy for optimizing infant medication dosage has been proposed [17].

Bayesian methods

PK/PD models, bedside drug testing, and electronic decision support systems can all be used to enable precision dosing in newborns. These techniques are based on Bayesian analytic techniques. The application of Bayesian-based dosing strategies (maximum posterior, MAP) that incorporate models of population pharmacokinetics and variables unique to each patient enables us to forecast drug concentrations, ideal dosage schedules, and the probabilities required to attain the reference (target) concentrations in individual patients through a computer simulation [18].

Certain features of Bayesian models lend themselves to practical application. (a) They have access to all accessible data, and (b) the Bayesian technique to statistical inference yields a more straightforward and understandable result than the old approach. The Bayesian approaches are especially well-suited for decision-making problems due to the previously mentioned factors. When administering several antibiotics to newborns, these techniques have shown to be beneficial,

greatly raising the frequency at which goal concentrations were reached [18].

The right antibiotic treatment regimen and duration are crucial for minimizing antibiotic misuse and overuse in neonates. These conditions can lead to a number of negative outcomes, such as antibiotic resistance, an elevated risk of necrotizing enterocolitis, invasive candidiasis, and viral and bacterial superinfections, mortality, and long-term consequences like obesity in early childhood and chronic diseases later in life [19].

The goal of antimicrobial stewardship programs (ASP) is to select the best antibiotic regimen, dose, duration, and route of administration using a multidisciplinary approach in order to maximize the appropriateness of antimicrobial prescriptions and minimize side effects. As a result, hospital and/or clinical pharmacists might participate in ASPs to support the responsible use of antibiotics. According to a recent comprehensive analysis, pharmacist involvement in ASPs lowers the use and length of antibiotic treatment in critically sick neonates [20].

Conclusion

Variability in reactions to antimicrobial drugs arises from underlying differences in physiologic and immunologic functions between adults and paediatrics. This variability may result in unintended harmful effects and subtherapeutic levels in paediatric patients. This emphasizes how crucial it is to comprehend the immunologic and physiologic alterations brought about by growth and development. For experimental medications, regulatory bodies are demanding more sophisticated antimicrobial PK-PD data. To a minimum, PK data are now needed for paediatrics for any agent applying for FDA approval for adult usage. PK/PD outcome data, however, are essentially non-existent for youngsters. Insufficient research on PK-PD in paediatrics is a significant obstacle to reasonable medication dosing, underscoring the need for sufficient paediatric research in the future.

Reference

[1] Van den Anker JN, McCune S, Annaert P, Baer GR, Mulugeta Y, Abdelrahman R, et al. Approaches to dose finding in neonates, illustrating the variability between neonatal drug development programs. Pharmaceutics. 2020 Jul 20;12(7):685. doi:10.3390/pharmaceutics12070685

[2] Puopolo KM, Mukhopadhay S, Frymoyer A, Benitz WE. The term newborn: early-onset sepsis. Clinics in Perinatology. 2021 Aug 1;48(3):471-84.

[3] Rallis D, Giapros V, Serbis A, Kosmeri C, Baltogianni M. Fighting Antimicrobial Resistance in Neonatal Intensive Care Units: Rational Use of Antibiotics in Neonatal Sepsis. Antibiotics. 2023 Mar 3;12(3):508.

[4] Regazzi M, Berardi A, Picone S, Tzialla C. Pharmacokinetic and pharmacodynamic considerations of antibiotic use in neonates. Antibiotics. 2023 Dec 18;12(12):1747. doi:10.3390/antibiotics12121747

[5] Smits A, Annaert P, Cavallaro G, De Cock PA, de Wildt SN, Kindblom JM, Lagler FB, Moreno C, Pokorna P, Schreuder MF, Standing JF. Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. British journal of clinical pharmacology. 2022 Dec;88(12):4965-84.

[6] van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Pediatric clinical pharmacology. 2011:51-75.

[7] Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. American Journal of Health-System Pharmacy. 2019 Sept 16;76(19):1472–80. doi:10.1093/ajhp/zxz161

[8] Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of antibiotics in pediatric intensive care: Fostering variability to attain precision

medicine. Antibiotics. 2021 Sept 28;10(10):1182. doi:10.3390/antibiotics10101182

[9] Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates. The Journal of Clinical Pharmacology. 2016 Aug;56(8):909-35.

[10] Hartman SJ, Brüggemann RJ, Orriëns L, Dia N, Schreuder MF, De Wildt SN. Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature. Clinical pharmacokinetics. 2020 Feb;59:173-205.

[11] Le J, Bradley JS. Pharmacodynamic considerations and special populations: Pediatrics. Methods in Pharmacology and Toxicology. 2016;561–97. doi:10.1007/978-1-4939-3323-5_22

[12] Rao GG, Landersdorfer CB. Antibiotic pharmacokinetic/pharmacodynamic modelling: Mic, pharmacodynamic indices and beyond. International Journal of Antimicrobial Agents. 2021 Aug;58(2):106368. doi:10.1016/j.ijantimicag.2021.106368

[13] Le J, Bradley JS. Optimizing antibiotic drug therapy in pediatrics: Current State and future needs. The Journal of Clinical Pharmacology. 2018 Sept 24;58(S10). doi:10.1002/jcph.1128

[14] Zhu F. Optimization of pediatric antibiotic dosing through therapeutic drug monitoring. Current Treatment Options in Pediatrics. 2022 Oct 3;8(4):382–94. doi:10.1007/s40746-022-00259-6

[15] Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence—implications for human health and treatment perspectives. EMBO reports. 2020 Dec 3;21(12). doi:10.15252/embr.202051034

[16] Green D, Amspacher V. Pediatric clinical trial design and dosing. Fundamentals of Pediatric Drug Dosing. 2016;45–63. doi:10.1007/978-3-319-43754-5_4

[17] Brussee JM, Calvier EA, Krekels EH, Välitalo PA, Tibboel D, Allegaert K, et al. Children in clinical trials: Towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Review of Clinical Pharmacology. 2016 Jun 27;9(9):1235–44. doi:10.1080/17512433.2016.1198256

[18] Pérez-Blanco JS, Lanao JM. Model-Informed Precision Dosing (MIPD). Pharmaceutics 2022, 14, 2731.

[19] Ting JY, Roberts A. Association of early life antibiotics and health outcomes: Evidence from clinical studies. InSeminars in Perinatology 2020 Dec 1 (Vol. 44, No. 8, p. 151322). WB Saunders.

[20] Lee SY, An SH. Impact of pharmacist intervention in antibiotic stewardship programmes for critically ill neonates: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics. 2022 Apr;47(4):430-44.